MyoKardia Conference Call to Discuss Danicamtiv Phase 2a Study June 22, 2020 at 8:30 AM EDT Click here for webcast Supporting Materials Danicamtiv (MYK 491) A Novel Small Molecule Cardiac Activator: in vitro/in vivo Evidence for Overall Myocardial Inotropy Phase 2a Study of Danicamtiv (MYK 491) in Patients with Chronic Heart Failure with Reduced Ejection Fraction ( HFrEF )
Danicamtiv (MYK 491) A Novel Small Molecule Cardiac Activator: in vitro/in vivo Evidence for Overall Myocardial Inotropy
Phase 2a Study of Danicamtiv (MYK 491) in Patients with Chronic Heart Failure with Reduced Ejection Fraction ( HFrEF )
